European Union - English - EMA (European Medicines Agency)

dechra regulatory b.v. - meloxicam - musculo-skeletal system, anti-inflammatory and anti-rheumatic products, non-steroids - dogs; cats - catsalleviation of inflammation and pain in chronic musculoskeletal disorders.dogsalleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.

New Zealand - English - Ministry for Primary Industries

le vet beheer b.v. - meloxicam - meloxicam 1.5 g/litre - anti-inflammatory

New Zealand - English - Ministry for Primary Industries

le vet beheer b.v. - meloxicam - meloxicam 0.5 g/litre - anti-inflammatory

United Kingdom - English - VMD (Veterinary Medicines Directorate)

le vet b.v. - meloxicam - oral suspension - anti inflammatory nsaid - cats

United Kingdom - English - VMD (Veterinary Medicines Directorate)

le vet b.v. - meloxicam - oral suspension - anti inflammatory nsaid - dogs

United Kingdom - English - VMD (Veterinary Medicines Directorate)

dechra regulatory bv - meloxicam - oral suspension - anti inflammatory nsaid - cats

United Kingdom - English - VMD (Veterinary Medicines Directorate)

dechra regulatory bv - meloxicam - oral suspension - anti inflammatory nsaid - dogs

United States - English - NLM (National Library of Medicine)

henry schein animal health - meloxicam (unii: vg2qf83cgl) (meloxicam - unii:vg2qf83cgl) - meloxicam 1.5 mg in 1 ml - eloxioral oral suspension is indicated for the control of pain and inflammation associated with osteoarthritis in dogs. dogs with known hypersensitivity to meloxicam should not receive eloxioral oral suspension. do not use eloxioral oral suspension in cats. acute renal failure and death have been associated with the use of meloxicam in cats.

United States - English - NLM (National Library of Medicine)

international laboratories, llc - meloxicam (unii: vg2qf83cgl) (meloxicam - unii:vg2qf83cgl) - meloxicam 7.5 mg - meloxicam tablets are indicated for relief of the signs and symptoms of osteoarthritis [see  clinical studies (14.1) ]. meloxicam tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis [see  clinical studies (14.1)]. meloxicam tablets are indicated for relief of the signs and symptoms of pauciarticular or polyarticular course juvenile rheumatoid arthritis in patients who weigh ≥60 kg [see dosage and administration (2.4) and clinical studies (14.2) ]. meloxicam is contraindicated in the following patients: • known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to meloxicam or any components of the drug product [see warnings and precautions (5.7, 5.9) ] • history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7,5.8) ] • in the setting of coronary artery bypass graft (cabg) surger

United States - English - NLM (National Library of Medicine)

american health packaging - meloxicam (unii: vg2qf83cgl) (meloxicam - unii:vg2qf83cgl) - meloxicam 15 mg - meloxicam tablets are indicated for relief of the signs and symptoms of osteoarthritis [see clinical studies (14.1)]. meloxicam tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis [see clinical studies (14.1)]. meloxicam tablets are indicated for relief of the signs and symptoms of pauciarticular or polyarticular course juvenile rheumatoid arthritis in patients who weigh ≥60 kg [see dosage and administration (2.4) and clinical studies (14.2)]. meloxicam is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to meloxicam or any components of the drug product [see warnings and precautions (5.7, 5.9)] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic r